MorphoSys ^{Priced, Nasdaq: MOR}

We are a late-stage biopharmaceutical company developing innovative and differentiated therapies for patients suffering from serious diseases. Based on our proprietary technology platforms and leadership in the field of therapeutic antibody discovery, generation and engineering, we, together with our partners, have participated in the development of more than 100 therapeutic product candidates. Our broad pipeline spans two business segments: Proprietary Development, in which we invest in and develop product candidates, and Partnered Discovery, in which we generate product candidates for our partners in the pharmaceutical and biotechnology industries against targets identified by our partners. We currently have 28 product candidates in clinical development, including our most advanced proprietary product candidate, MOR208, for the treatment of relapsed or refractory diffuse large B cell lymphoma, or r/r DLBCL. MOR208 received breakthrough therapy designation from the FDA in 2017 in combination with lenalidomide for r/r DLBCL patients ineligible for high-dose chemotherapy and autologous stem cell transplants. Also in 2017, Tremfya, developed by our partner Janssen, became the first therapeutic antibody based on our proprietary technology to reach the market.